Iovance Biotherapeutics, Inc. - Common Stock (IOVA)
6.0300
-0.1800 (-2.90%)
Iovance Biotherapeutics is a clinical-stage biotechnology company focused on the development and commercialization of novel cell therapy products for the treatment of cancer
The company specializes in the use of tumor-infiltrating lymphocyte (TIL) therapy, which harnesses the body’s immune system to target and destroy cancer cells. By processing and expanding patients' own immune cells, Iovance aims to create personalized therapies that can provide effective options for those with various types of solid tumors. Their innovative approach leverages advancements in cell therapy to improve patient outcomes and contribute to the evolving landscape of cancer treatment.
SAN CARLOS, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQIOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on January 16, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 224,550 shares of Iovance’s common stock to forty-one new, non-executive employees.
Shares of Iovance Biotherapeutics, Inc. (NASDAQIOVA) are trading lower Friday. The company announced the inducement stock option grants under Nasdaq Listing Rule 5635(c)(4).
SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQIOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on December 19, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 203,980 shares of Iovance’s common stock to forty-eight new, non-executive employees.
SAN CARLOS, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQIOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Raj Puri, M.D., Ph.D. has been promoted to the newly created role of Chief Regulatory Officer. Dr. Puri joined Iovance in March 2022 as Executive Vice President, Regulatory Strategy and Translational Medicine.
